Neurocrine Biosciences, Inc.
NBIX
$102.88
-$5.43-5.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.68% | 102.04% | 92.29% | 477.66% | 61.62% |
| Total Depreciation and Amortization | 27.23% | 28.50% | 33.51% | 30.06% | 36.54% |
| Total Amortization of Deferred Charges | -- | -100.00% | 34,500.00% | 10,987.50% | -- |
| Total Other Non-Cash Items | 171.44% | 96.94% | 87.21% | -50.23% | -61.49% |
| Change in Net Operating Assets | -168.09% | -307.96% | -768.09% | 209.96% | 141.84% |
| Cash from Operations | 52.71% | 16.37% | 79.07% | 153.40% | 14.88% |
| Capital Expenditure | -34.98% | -46.96% | -132.47% | -78.16% | -71.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.81% | 28.55% | -20.82% | -252.16% | -272.18% |
| Cash from Investing | 72.85% | 31.66% | -10.84% | -155.86% | -163.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 86.98% | 170.64% | 197.03% | 171.37% | 46.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -845.33% | -395.96% | -458.60% | 154.69% | 127.87% |
| Foreign Exchange rate Adjustments | -100.00% | 146.15% | 123.08% | 123.08% | 123.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.03% | -32.19% | -606.90% | 275.90% | 84.17% |
